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Abstract
Background: [1,2,4] triazolo [4, 3-a][1,8]naphthyridine derivatives (including NF161 and NF177) were tested for anti-
inflammatory, analgesic and antipyretic properties and for their effects on spontaneous locomotor activity in mice and
acute gastrolesivity in rats. Both NF161 and NF177 appeared to be anti-inflammatory and analgesic agents without toxic
effects or acute gastrolesivity, but NF161 showed stronger anti-inflammatory activity, whereas NF177 was more active
as analgesic.
Methods: An EIA kit was used to investigate the ability of NF161 and NF177 to affect prostaglandin E2 (PGE2) and
prostacyclin (PGI2) production by human umbilical vascular endothelial cells (HUVEC).
The compounds' effects on the production of reactive oxygen species (ROS) by human polymorphonuclear cells (PMNs)
were studied in an in vitro cell model, evaluating inhibition of superoxide anion (O2-.) production induced by N-
formylmethionyl-leucyl-phenylalanine (FMLP). Their effects on PMN adhesion to HUVEC were also investigated; they
were incubated with PMNs and endothelial cells (EC) and challenged by stimuli including Platelet Activating Factor (PAF),
FMLP, Phorbol Myristate Acetate (PMA), Tumor Necrosis Factor-α (TNF-α) and Interleukin-1β (IL-1β). Adhesion was
quantitated by computerized micro-imaging fluorescence analysis.
Results: Neither compounds modified PGE2 or PGI2 production induced by IL-1α.
O2-. production and myeloperoxidase release from PMNs stimulated by FMLP was inhibited in a dose- but not time-
dependent manner by both [1,8]naphthyridine derivatives, NF161 being statistically more active than NF177 (P < 0.01).
The compounds inhibited adhesion evoked by the pro-inflammatory stimuli PAF, FMLP, TNF-α and IL-1β in a
concentration-dependent manner in the 10-6–10-4M range, being more active when PAF was used as stimulus and inactive
when cells were challenged by PMA. Both compounds acted both on PMN and HUVEC.
Conclusion: Considering the interesting anti-inflammatory effects of these compounds in in vivo models and the absence
of acute gastrolesivity, the study improved knowledge of anti-inflammatory properties of NF161 and NF177, also
demonstrating their potential in vitro, through inhibition of O2-. production, myeloperoxidase release and PMN adhesion
to HUVEC. Negative results on PG production suggest a cyclooxygenase (COX)-independent mechanism.
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There is currently considerable therapeutic interest in
novel anti-inflammatory drugs with mechanisms other
than the inhibition of cyclooxigenase activity, typical of
nonsteroidal anti-inflammatory drugs (NSAIDs), and
thus devoid of irritant effects on the gastric mucosa and
suitable for use in chronic inflammatory diseases. COX is
the enzyme that catalyses the first two steps in the biosyn-
thesis of prostaglandins (PGs) from arachidonic acid [1].
About a decade ago it was demonstrated that COX exists
as at least two distinct isoforms, COX-1 and COX-2, both
responsible for PG production in a range of tissues.
HUVEC are known to possess both COX isoforms. COX-
1 is constitutive and its expression cannot be modulated,
while COX-2 induction in HUVEC has been demon-
strated in response to various proinflammatory cytokines,
such as IL-1α and β and TNF-α [2,3].
[1,8]naphthyridine derivatives have been reported to pos-
sess antibacterial [4], antymicobacterial [5], antitumoral
[6], anti-inflammatory [7], antiplatelet [8], gastric antisec-
retary [9], antiallergic [10], local anaesthetic [11] and ben-
zodiazepine receptor activities [12]. [1,8]naphthyridine
derivatives are also reportedly associated with positive
ionotropic [13], β-adrenergic blocking [14] and anti-
hypertensive [15] activities. Recently, Roma et al. [16] syn-
thesized a series of new derivatives, the substituted 5-
amino[1,2,4]triazolo [4.3-a][1,8]naphtyridine-6-carboxa-
mides, in order to obtain novel interesting anti-inflamma-
tory agents. The authors showed that compound NF161
(Fig. 1) exhibited potent statistically-significant anti-
inflammatory activity at the carrageenan-induced paw
edema assay in rats, and showed interesting anti-aggres-
sive activity (even if only at the highest dose) evaluated in
the isolation-induced aggressiveness test in mice; results
of a further test at 50 mg/Kg dose to evaluate antinocicep-
tive activity of this compound were not statistically signif-
icant. This compound has since been demonstrated to
have marked analgesic activity at the acetic-acid-induced
writhing test in mice (at 200 and 100 mg/kg) and a com-
plete lack of acute gastrolesivity in rats [17].
The same paper described a new compound (NF177, Fig.
1), belonging to the same chemical family [17]. In com-
parison with NF161, NF177 demonstrated stronger anal-
gesic activity in the writhing test in mice, remarkably
lower anti-inflammatory activity in the carrageenin-
induced paw edema assay in rats (being active only at the
highest dose), a marked effect on locomotor activity in
mice and, like NF161, a complete lack of acute gastrolesiv-
ity in rats.
Bone-marrow-derived leukocytes, in particular PMNs, are
responsible for much of the damage in chronic inflamma-
tion reactions. ECs play a crucial role in leukocyte homing
to tissues, through adhesive interactions with these cells.
These processes depend on specific cell adhesion mole-
cule (CAM) activity in leukocytes and ECs. CAM activity
can be regulated by modulating their expression or intrin-
sic adhesive functions [18]. PMNs maintain several of
these receptors in an inactive state during transit in the
bloodstream and extracellular fluids, and only activate
Structures of NF161 and NF177Figure 1
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important role in this signaling is played by molecules
belonging to the chemoattractant family, which com-
prises classic chemoattractants such leukotriene B4, PAF,
N-formyl peptides and chemokines, which are cytokines
with chemoattractant capacity and a high level of
sequence homology. Chemoattractants bind to the sur-
face of ECs, which present them to circulating PMNs.
PMN interaction with chemoattractants promotes
integrin adhesion via inside-out signaling [19], activates
cell motility, and stimulates degranulation and respira-
tory burst of phagocytes [20].
Since PMN adhesion to ECs is a key step in the develop-
ment and progression of inflammation, we investigated
the anti-inflammatory activity of NF161 and NF177, eval-
uating their ability to inhibit PMN adhesion to HUVEC,
induced by several stimuli; we also studied PMN adhesion
to FCS-coated plastic wells. PMN activation was deter-
mined via O2- production and myeloperoxidase release.
Both NF161 and NF177 inhibited O2-. production and
myeloperoxidase release from PMNs, challenged by
FMLP, NF161 being statistically more active than NF177.
Moreover, both compounds inhibited the PMN adhesion
to HUVEC evoked by pro-inflammatory stimuli, acting
either on PMNs or on HUVEC. Neither NF161 nor NF177
was able to modify the PGE2 and PGI2 production induced
by IL-1α in HUVEC, thus suggesting a COX-independent
mechanism of action.
Methods
Materials
Dextran T500 was from Pharmacia Biotech (Uppsala,
Sweden). Bovine calf serum (BCS, endotoxin tested) was
from Hyclone Laboratories Inc. (Logan, UT). Trypsin was
from Difco Laboratories Inc, Detroit, MI. Histo-
paque®1077, fluorescein diacetate, M199 (endotoxin
tested), PAF, n-FMLP, IL-1β, PMA, TNF-α, cytochrome C,
superoxide dismutase, cytochalasin B, HAS, 2-chloroade-
nosine and methylthiazolyldiphenyl-tetrazolium bro-
mide (MTT) were from Sigma-Aldrich (St. Louis, MO).
Collagenase was from Roche Diagnostics (Mannheim,
Germany). MAb LFA-1 (recognizes CD11a) was a gift
from Prof. U. Dianzani (University of Eastern Piedmont,
Novara, Italy). MAb OKM-1 (recognizes CD11b).
was obtained from the American Type Culture Collection
(Rockville, MD, USA). Each mAb was used at the concen-
tration that demonstrated maximal inhibitory effects in
the adhesion assay, (20 µg/ml) [21].
All other reagents and solvents were from Merck (Darm-
stadt, Germany). The [1,8]naphthyridine derivatives were
synthesized as reported in Grossi et., 2005 [17]. Each of
the [1,8]naphthyridine derivatives was dissolved in dime-
thyl sulphoxide (DMSO). Stock solutions were prepared
daily and diluted in M199 to the appropriate concentra-
tions before each experiment. The final concentration of
DMSO was never above 0.1%. The same amount of
DMSO was added to controls and did not affect absolute
control adhesion nor superoxide anion production (O2-.).
Cell cultures
PMNs were prepared from citrated venous blood obtained
from healthy volunteers at a local hospital bank, using the
standard techniques of dextran sedimentation followed
by Histopaque®1077 gradient centrifugation. Residual
erythrocytes were removed by hypotonic lysis and PMNs
were resuspended in buffered salt solution (BSS) (138
mmol/l NaCl, 2.7 mmol/l KCl, 8.1 mmol/l Na2HPO4, 1.5
Effects of NF161 and NF177 on FMLP-evoked O2-. produc-tion by PMNsFigure 2
Effects of NF161 and NF177 on FMLP-evoked O2-. produc-
tion by PMNs. The results are expressed as percentage inhi-
bition of O2-. production evoked by 10-7M FMLP in the 
absence of NF161 and NF177: this production amounted to 
2.1 ± 0.3 nmol cytochrome C reduced/106 cells/min and was 
taken as 100%. Data are expressed as means ± SEM; n = 5. 
Asterisks mark statistically significant inhibition of NF161 
versus NF177 (**P < 0.01).Page 3 of 11
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7.4) supplemented with 1 mg/ml glucose and 1 mg/ml
human serum albumin (HSA). Purity of the final cell sus-
pension and cell viability, assessed by the trypan blue
exclusion test, were > 95% in all cases. Cell viability was
not affected by compound treatments, measured with the
MTT test [22] for HUVEC and with the trypan blue exclu-
sion test for PMNs (test time: 0–25 min; concentration 10-
4M).
HUVEC were isolated as described elsewhere [23] from
human umbilical veins by collagenase treatment (0, 1%)
and cultured on gelatin-coated culture dishes in M199
medium supplemented with 20% heat-inactivated bovine
calf serum (BCS), 100 U/ml penicillin, 100 µg/ml strepto-
mycin, 5 U.I./ml heparin, 12 µg/ml bovine brain extract
and 200 mM glutamine. HUVEC were grown to conflu-
ence in flasks and used at the II-IV passages.
Superoxide anion (O2-.) production
PMNs (1 × 10-6cells/ml) were suspended in buffer saline
solution (BSS); they were pretreated with cytochalasin B
(5 µg/ml) for 5 min at 37°C to maximize the measured
response, then challenged with the test compound for 15–
25 min at 37°C before exposure to 10-7M FMLP for a fur-
ther 5 min. O2-. production was determined spectrophoto-
metrically by measuring the superoxide dismutase-
inhibitable reduction of cytochrome C reduced/106
PMNs/min. NF161 and NF177 were checked for interfer-
ence in the assay by measuring their effects on cytochrome
C reduction with a xanthine oxidase superoxide generat-
ing system. Neither of the compounds tested interfered
with the spectrophotometric assay. Assays were carried
out in the same buffer, with 100 µM cytochrome C, 150
µM hypoxanthine, 0.01 units of xanthine oxidase per mil-
liliter, and appropriate concentrations of each com-
pounds.
Myeloperoxidase assay
PMNs (2 × 106 cells) were incubated in BSS to a final vol-
ume of 1 ml with cytochalasin B and NF161 or NF177 for
15 min, than FMLP (10-8M) was added for a further 5 min.
Myeloperoxidase release was assayed as described by Hen-
son et al. [24]. Release of enzymes was expressed as per-
centage of total cell enzyme activity.
Adhesion assay
HUVEC were grown to confluence in 24-well plates.
PMNs (107cells/ml) were labeled with fluorescein diace-
tate (5 µg/ml) for 30 min at 37°C, washed with BSS, and
plated at 106 cells/well in a final volume of 0.25 ml BSS on
HUVEC pretreated with the 1, 8-naphtyridines (10-6–10-
4M) for 10 min and challenged with various stimuli:
FMLP and PAF (both at 10-7M) or PMA (10-8M) for 10
min or IL-1β and TNF-α (both at 10 ng/ml) for 1 h. After
incubation, non-adherent PMNs were removed by wash-
ing three times with 1 ml BSS. The center of each well was
analyzed by fluorescence image analysis [25]; adherent
cells were counted using Image Pro Plus Software for
micro-imaging (Media Cybernetics, version 5.0). Single
experimental points were assayed in quadruplicate, and
the standard error of the four replicates was below 10% in
all cases. Data are presented as percentage adhesion versus
the control value, control adhesion being measured on
HUVEC that underwent no treatment. Control adhesion
was 51 ± 9 cells/microscope fields (n = 30).
The direct effect on HUVEC was assessed by pretreated the
cells with the 1, 8-naphtyridines (10-4M) and 10-7M PAF
for 20 min, washed three times and challenged with
PMNs for further 10 min.
The direct effect on PMNs was assessed by seeding the
cells on 24-well EC-free plates for 20 min at 37°C, in the
Effects of NF161 and NF177 on FMLP-evoked myeloperoxi-dase release by PMNsFigu  3
Effects of NF161 and NF177 on FMLP-evoked myeloperoxi-
dase release by PMNs. The results are expressed as percent-
age inhibition of myeloperoxidase release evoked by 10-8M 
FMLP in the absence of NF161 and NF177: this release 
amounted to 31 ± 6%. Data are expressed as means ± SEM; n 
= 5. Asterisks mark statistically significant inhibition of NF161 
versus NF177 (*P < 0.05, **P < 0.01).Page 4 of 11
(page number not for citation purposes)
Journal of Inflammation 2006, 3:4 http://www.journal-inflammation.com/content/3/1/4presence of NF161 or NF177 and 10-7M FMLP. The plates
had previously been coated with heat-inactivated calf
serum for three hours to reduce spontaneous adhesion to
the plastic wells. Percentage inhibition of adhesion was
calculated as follows: [100 - (a)/(b)] × 100, where a is
adhesion measured in the presence of the compound plus
stimulus minus basal adhesion, and b is adhesion elicited
by stimulus minus basal adhesion.
Prostacyclin and Prostaglandin E2 enzyme immunoassay
The effect of IL-1α on the release of PGE2 and the stable
metabolite of prostacyclin, 6-keto-PGF1α, were estab-
lished by incubating HUVEC in the presence of IL-1α (10
ng/mL) for 20 h. After incubation, the medium was col-
lected and analyzed for PGE2 and 6-keto-PGF1α. On the
basis of the data obtained in this experiment, the effect of
NF161 and NF177 on the release of PGE2 and 6-keto-
PGF1α, in IL-1α-treated HUVEC was studied. HUVEC were
pretreated for 20 h with IL-1α plus either NF177 or NF161
(10-6–10-4M). In a second set of experiments, HUVEC
were pre-treated with IL-1α for 20 h and then with NF177
or NF161 (10-6–10-4M) for a further 30 min. The PGE2
and 6-keto-PGF1α content of the media were assayed using
the Amersham Biosciences enzyme immunoassay kit
(Amersham Biosciences Corp., Piscataway, NJ, USA) and
following the manufacturer's protocol.
Statistical analysis
Results are expressed as means ± SEM; n indicates the
number of experiments. Data in Fig. 2, 3, 4, 5, 6, 7 were
analyzed by two-way analysis of variance to ascertain
whether differences among the means were significant.
The Bonferroni multiple comparison post-test was then
applied to determine significant differences between spe-
cific pairs of means. The molar concentration of each
compound that reduces response to the stimulus by 50%
(IC50) was calculated with a non-linear regression model
using the software Origin version 6.0 (Microcal Software,
Northampton, USA). IC50 data in Figures 4 and 5 were
analyzed using one-way analysis of variance, followed by
the Tukey multiple comparison post-test. Differences were
considered to be statistically significant at a value of P <
0.05. All statistical analyses were done using GradPad-
Prism 3.0 software (GraphPad Software, San Diego, Cali-
fornia, USA).
Results and discussion
Effect of NF161 and NF177 on IL-1α-induced PGE2 and 
PGI2 production by HUVEC
The compounds NF161 and NFF177 had previously been
tested in vivo for their anti-inflammatory effects [16,17].
In the carrageenin induced rat paw edema test, compound
NF161 exhibited statistically significant anti-inflamma-
tory activity in the dosage range 6.25–200 mg/Kg, while
compound NF177 only did so at 200 mg/Kg. However,
their mechanism of action had not been demonstrated.
The aim of the present study was to investigate how these
compounds exert their anti-inflammatory effects. The first
mechanism we focused on was inhibition of the COX
pathway, as COX is one of the most important enzymes
Effects of NF161 on PMN adhesion to HUVEC evoked by PAF, FMLP, IL-1β, TNF-α nd PMAFigure 4
Effects of NF161 on PMN adhesion to HUVEC evoked by 
PAF, FMLP, IL-1β, TNF-α and PMA. HUVEC were pretreated 
with increasing concentrations (10-6–10-4M) of the tested 
compound for 10 min at 37°C and then challenged with PAF, 
FMLP (both at 10-7M) or PMA (10-8M) and PMNs for a fur-
ther 10 min; IL-1β and TNF-α (both at 10 ng/ml) were incu-
bated 1 h with the pretreated HUVEC and then challenged 
with PMNs for a further 10 min. Data are expressed as per-
centage inhibition versus control adhesion. Control adhesion 
was 51 ± 9 cells/microscope field (mean ± SEM, n = 26). PAF, 
FMLP, IL-1β, PMA and TNF-α stimulation vs control was, 
respectively: 305 ± 37%, 283 ± 28%, 270 ± 23%, 340 ± 46% 
and 304 ± 29%. Data are expressed as means ± SEM; n = 5. 
IC50 values were: 9.2 ± 0.7 × 10-6M, 3.7 ± 0.3 × 10-5M, 6.4 ± 
0.4 × 10-5M and 3.1 ± 0.5 × 10-5M when the stimulus used 
was PAF, FMLP, IL-1β and TNF-α, respectively. IC50 values 
obtained with PAF were statistically different from all others 
(P < 0.01). Asterisks mark statistically significant inhibition of 
NF161 using PAF as stimulus versus all other stimuli (**P < 
0.01).Page 5 of 11
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Most anti-inflammatory drugs exert their effects by inhib-
iting this pathway. COX has been found in two isoforms,
and COX-2 is an inducible form responsible for the pro-
duction of large amounts of pro-inflammatory PGs at sites
of inflammation. For this reason we measured PG produc-
tion in HUVEC. Caughey et al. [2] demonstrated that pre-
treatment with IL-1α induces COX-2 expression in
HUVEC, with a corresponding increase in PG release.
Here, we report that IL-1α stimulation of HUVEC for 20 h
induced COX activity, generating high level of PGE2 and
the stable metabolite of prostacyclin, 6-keto-PGF1α (Table
1). PGE2 synthesis was drastically increased by IL-1α from
the basal level (45 ± 8 pg/well) to 280 ± 29 pg/well (n =
3). Similarly, a massive release of 6-keto-PGF1α was
detected in IL-1α-treated HUVEC. When NF161 or NF177
were added simultaneously with IL-1α, neither com-
pound significantly modified PGE2 or PGI2 production in
the 10-6–10-4M concentration range. Indomethacin 10-
5M, used as positive control, inhibited PGE2 and PGI2 pro-
duction almost completely (data not shown). These
results demonstrate that NF161 and NF177 do not affect
COX activity in HUVEC. As they do not modify PGE2 or
PGI2 production. we might conclude that the mechanism
of action of NF161 and NF177 does not involve COX
enzymes (Table 1).
Effect on O2-. production induced by FMLP on PMNs
Considering that the effects of NF161 and NF177 do not
involve the COX pathway, we next investigated whether
these compounds could interfere with other cellular
mechanism(s) involved in the inflammatory process.
With the aim of evaluating the ability of NF161 and
NF177 to interfere with the oxidative burst of human neu-
trophils, we measured O2-. production by PMNs in the
presence and in the absence of these compounds. Neither
of the tested compounds alone induced O2-. production
by PMNs in the concentration range 10-6–10-4M (data not
shown). PMNs challenged with 10-7M FMLP released O2-
.(2.1 ± 0.3 nmol citochrome C reduced/106 cells/min; n =
5). This concentration was selected as suitable to produce
optimal O2-. generation by human PMNs [26]. When
PMNs were incubated with increasing concentrations of
the two compounds (10-6–10-4M) for 10 min and then
challenged with 10-7M FMLP, an inhibitory effect on O2-.
production was detected (Fig. 2). Both compounds dose-
dependently inhibited O2-. production evoked by 10-7M
FMLP. Maximal inhibition was obtained at 10-4M. NF161
percentage inhibition vs control was 98 ± 1% and its IC50
= 2.1 ± 0.4 × 10-5M; the inhibition of O2-. production
induced by NF177 was lower (**p < 0.01: NF161 vs
NF177), being 83 ± 4%, and its IC50 = 2.5 ± 0.5 × 105 M.
Even when in cubation time was prolonged (30 min; data
not shown), the substances tested were still able to inhibit
O2-. production, with a dose-response curve quantitatively
and qualitatively equal to those depicted above in Fig. 2.
2-chloroadenosine, a well known modulator of PMN
functions, used as positive control [27], caused greater
inhibition than the tested compounds, with maximum
effect of 70 ± 4% inhibition, and IC50 = 87 ± 6 × 10-9M.
Fiorucci et al. [28] have shown that 10-4M indomethacin,
Effects of NF177 on PMN adhesion to HUVEC evoked by PAF, FMLP, IL-1β, TNF-α nd PMAFigure 5
Effects of NF177 on PMN adhesion to HUVEC evoked by 
PAF, FMLP, IL-1β, TNF-α and PMA. HUVEC were pretreated 
with increasing concentrations (10-6–10-4M) of the tested 
compound for 10 min at 37°C and then challenged with PAF, 
FMLP (both at 10-7M) or PMA (10-8M) and PMNs for a fur-
ther 10 min; IL-1β and TNF-α (both at 10 ng/ml) were incu-
bated for 1 h with the pretreated HUVEC and then 
challenged with PMNs for a further 10 min. Data are 
expressed as percentage inhibition versus control adhesion. 
PAF, FMLP, IL-1β, PMA and TNF-α stimulation vs control 
was, respectively: 305 ± 37%, 283 ± 28%, 270 ± 23%, 340 ± 
46% and 304 ± 29%. Data are expressed as means ± SEM; n = 
5. IC50 values were: 1.7 ± 0.6 × 10-6M, 2.6 ± 0.5 × 10-5M, 9.4 
± 0.4 × 10-5M and 3.9 ± 0.5 × 10-5M when the stimulus used 
was PAF, FMLP, IL-1β and TNF-α, respectively. IC50 values 
obtained with PAF were statistically different from all others 
(P < 0.01). Asterisks mark statistically significant inhibition of 
NF177 using PAF as stimulus versus all other stimuli (**P < 
0.01).Page 6 of 11
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production, and Zimmerli et al. [29] demonstrated that
10-5M indomethacin did not inhibit superoxide produc-
tion induced by FMLP. Consequently, in this experimen-
tal model, NF161 and NF177 acted through a different
mechanism than that of indomethacin.
Reactive Oxygen Species (ROS), such as O2-., are produced
in all aerobic organisms during respiration and exist in the
cell in equilibrium with endogenous antioxidants (e.g.
glutathione, vitamins A, C and E). Excess production of
ROS alters cellular redox balance. ROS react with many
macro molecules causing structural and functional modi-
fications, cytotoxicity and mutagenic damage [30]. ROS
exert genomic effects and modulate cell proliferation, by
activating transcription factors such as AP-1, AP-2 and NF-
kB [31]. Leukocytes (particularly PMNs and monocytes)
and ECs provide a rich source of ROS, that can contribute
to the development of degenerative pathologies (e.g.
atherosclerosis, diabetes, Alzheimer's disease, arthritis,
multiplesclerosis). ROS also play an important role in
evolving organ injury (e.g. cerebral, cardiac, intestinal
damage), which characterizes the pathophysiology of
ìschemia-reperfusion (I/R) [32]. Therefore the ability of
these [1,8] naphthyridine derivatives to inhibit O2-. pro-
duction demonstrates their role in modulating oxidative
stress and suggests their potential use in various degener-
ative diseases.
Effect on myeloperoxidase release induced by FMLP on 
PMNs
With the aim of evaluating whether NF161 and NF177 are
only capable of interfering with the O2-.production by
PMNs, myeloperoxidase release in the presence and in the
absence of these compounds was measured. Neither of
the compounds tested induced myeloperoxidase release
from non-stimulated PMNs in the concentration range
10-6–10-4M (data not shown). PMNs challenged with 10-
8M FMLP were able to release myeloperoxidase (31 ± 6%;
n = 5) and this concentration was selected as suitable for
producing optimal myeloperoxidase release by human
PMNs. When PMNs were incubated with increasing con-
centrations of the two compounds (10-6–10-4M) for 15
min and then challenged with 10-8M FMLP, an inhibitory
effect on myeloperoxidase release was detected (Fig. 3).
Both compounds dose-dependently inhibited myeloper-
oxidase release evoked by 10-8M FMLP. As in the O2-. pro-
duction test, NF161 induced a stronger inhibitory effect
than did NF177; maximal inhibition was obtained at 10-
4M. NF161 percentage inhibition vs control was 87 ± 5%
and its IC50 = 1.7 ± 0.4 × 10-5M; the inhibition of mye-
loperoxidase release induced by NF177 was lower (**p <
0.01; *p < 0.05: NF161 vs NF177), being 53 ± 6% and its
IC50 = 1.7 ± 0.3 × 10-5M.
Effect of NF161 and NF177 on PMN adhesion to HUVEC 
induced by different stimuli: FMLP, PAF, IL-1β, TNF-α and 
PMA
Adhesion and transendothelial migration of leukocytes
into the surrounding tissues are crucial steps in inflamma-
tion, immunity and atherogenesis [33,34,18]. The present
experiments were designed to ascertain whether NF161
and NF177 exert inhibitory effects on PMN adhesion to
HUVEC.
Control adhesion was 51 ± 9 cells/microscope field (mean
± SEM, n = 30). Neither of the substances (at 10-6–10-4M)
affected PMN adhesion of resting cells (data not shown),
while indomethacin, (10-4M), in the same experimental
model, behaved differently, markedly increasing PMN
adhesion to HUVEC [28]. Thus HUVEC were pretreated
for 10 min with the tested compounds (10-6–10-4M) and
Effects of NF161 on PMN adhesion to FCS-coated plastic wells c mpared with PMN adhesion to HUVECFigure 6
Effects of NF161 on PMN adhesion to FCS-coated plastic 
wells compared with PMN adhesion to HUVEC. PMNs were 
incubated with increasing concentrations (10-6–10-4M) of the 
tested compound for 10 min at 37°C and then challenged 
with FMLP 10-7M for 10 min. FMLP stimulation vs control 
was: 323 ± 33%. Data are expressed as percentage inhibition 
versus control adhesion, as means ± SEM; n = 5.Page 7 of 11
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PAF, 10-8M PMA, 10 ng/ml TNF-α and IL-1-β (see Meth-
ods). 10-7M FMLP-induced adhesion was 283 ± 28% vs
control: it has been shown that the tested concentration
produces near-maximal activation of PMNs [35,36,20].
Concentrations of the other stimuli were chosen on the
basis of published reports and our previous experimental
results, in order to achieve an adhesion close to that
obtained with FMLP [20,37,38].
Considering that the synthetic peptide FMLP, mimetic of
bacterial chemotaxins, only activates PMN adhesive
machinery, this stimulus was selected to evaluate the
effect of the compounds tested on PMNs. TNF-α and IL-1-
β preferentially act on EC [39-41], whereas PAF and PMA
activate both PMNs and HUVEC [20].
NF161 showed a dose-dependent inhibitory effect in the
concentration range 10-6–10-4M (Fig. 4), its inhibitory
effect decreasing in the following order, depending on the
stimulus used: PAF > FMLP TNF-α > IL-1-β > PMA (**P <
0.01, PAF vs FMLP, TNF-α, IL-1-β and PMA). The maxi-
mum inhibition was in all cases achieved at 10-4M, being
98 ± 2% with PAF, around 70–80% with FMLP, IL-1-β and
TNF-α and below 20% with PMA.
Similar results were obtained with NF177 (Fig. 5), reach-
ing higher inhibition effects using PAF and IL-1-β as stim-
ulus and no effect with PMA. This stimulus selectivity was
particularly interesting, because all the stimuli except
PMA are known to activate HUVEC or PMNs through
membrane receptors, whereas PMA is a direct protein
kinase C (PKC) activator [42,43]. In the same experimen-
tal condition, mAbs against the integrin adhesion mole-
cules LFA-1 and OKM-1 [44], used as positive controls,
exerted 92 ± 3% and 94 ± 5% inhibition, respectively.
These findings may suggest a direct action of these com-
pounds on membrane structures and/or on CAMs, rather
than through inhibition of an intracellular PKC pathway.
The role of CAMs in modulating PMN adhesion to ECs is
well known. The CAMs involved in leukocyte trafficking
constitute excellent targets for pharmacological modula-
tion of the cellular response in inflammation. Several
mechanisms can modulate the function of inflammatory
CAMs, including competitive blockade, altered expression
on the cell surface and interference with receptor activa-
tion. Several groups of pharmaceutical agents in use clini-
cally interfere with the function of CAMs either directly or
indirectly. Many clinical trials of anti-adhesion therapies
have used humanized antibodies, but low-molecular-
weight compounds have several advantages over antibod-
ies and are less likely to trigger adverse immune reactions
[45]. Therefore further direct evidence linking compounds
NF161 and NF177 to their potential ability to interact
with CAMs would be very useful to clarify their mecha-
nism of action.
Effects of NF161 and NF177 on PMNs or HUVEC
To better understand the selective effects of these com-
pounds on the two different cell populations, we firstly
evaluated their effects on PMN adhesion to FCS-coated
plastic wells, using FMLP as stimulus. Comparison of the
results obtained in this experimental system with those
obtained previously using EC showed that the concentra-
tion-response curves were similar, without any significant
difference, for both compounds (Fig. 6 and Fig. 7).
Indeed, the ability of NF161 and NF177 to inhibit PMN
adhesion can be regarded as a direct effect on PMNs,
HUVEC being absent in this experimental model. Second-
arily, we pretreated PAF stimulated HUVEC with (10-4M)
NF161 or NF177, washed three times and then added
Effects of NF177 on PMN adhesion to FCS-coated plastic wells c mpared with PMN adhesion to HUVECFigure 7
Effects of NF177 on PMN adhesion to FCS-coated plastic 
wells compared with PMN adhesion to HUVEC. PMNs were 
incubated with increasing concentrations (10-6–10-4M) of the 
tested compound for 10 min at 37°C and then challenged 
with FMLP 10-7M for 10 min. FMLP stimulation vs control 
was: 323 ± 33%. Data are expressed as percentage inhibition 
versus control adhesion, as means ± SEM; n = 5.Page 8 of 11
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are able to inhibit PMN adhesion to stimulated HUVEC
(% inhibition of NF161 = 81 ± 7; % inhibition of NF177
= 67 ± 6; n = 5), demonstrating that NF161 and NF177
can also act on EC. Moreover, when we used PAF, which
acts on both cell populations, the inhibition of PMN
adhesion to HUVEC evoked by NF161 and NF177 was
significantly higher than in all other cases. The concentra-
tion-response curves shifted leftwards by one order of
magnitude for NF161 (Fig. 4) and by two for NF177 (Fig.
5), demonstrating a synergistic effect of NF161 and
NF177 when both cell populations are stimulated simul-
taneously.
Leukocyte extravasation is due to the cooperative activity
of several molecules acting on both PMNs and HUVEC;
the rapid exertion of inhibition of adhesion, and the lack
of activity of the two compounds when the stimulus was
PMA, appear to indicate that NF161 and NF177 induce a
steric block of adhesion molecules activated by pro-adhe-
sive stimuli on PMNs and HUVEC. It is noteworthy that
synthetic compounds directed against CAMs might be
therapeutically effective partly because they block intrac-
ellular signaling events that are crucial for numerous
immune cell activities, such as motile responses, exocyto-
sis, cytokine production and the respiratory burst [46].
Conclusion
In summary, our in vitro results indicate that the in vivo
anti-inflammatory properties of compounds NF161 and
NF177 [16,17] do not involve the COX pathway, but may
be due to their anti-adhesive effects and their inhibition of
O2-. production and of myeloperoxidase release, these
properties being shown in vitro with steep concentration-
response curves and at high concentrations. The two com-
pounds exert their anti-adhesive effects very quickly,
inhibiting PMNs adhesion to HUVEC within 10–20 min,
acting directly either on HUVEC or on PMNs. Moreover,
the anti-adhesive effect increases markedly when both cell
populations are activated at the same time. The inhibitory
effect detected in the presence of FMLP, IL-1β and TNF-α
is also particularly interesting, since these experimental
conditions may be regarded as mimetic of pathophysio-
logical mechanisms of inflammatory diseases. The fea-
tures of NF161 and NF177, together with the in vivo anti-
inflammatory effects reported by other authors for
[1,8]naphthyridine derivatives and their absence of gas-
trotoxicity, may be interesting for the design and develop-
ment of innovative anti-inflammatory molecules in this
structural field.
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Table 1: Effect of NF161 and NF177 on PGE2 and PGI2 production by Il-1α-treated HUVEC
(a) PGE2(pg/well) 6-keto-PGF1α (pg/
well)
(b) PGE2 (pg/well) 6-keto-PGF1α (pg/
well)
Control 45 ± 8 797 ± 23 Control 58 ± 18 888 ± 30
IL-1α 280 ± 29 3391 ± 98 IL-1α 275 ± 22 4055 ± 22
NF161 10-4M 295 ± 31 3508 ± 82 NF161 10-4M 288 ± 17 3990 ± 38
NF161 10-5M 285 ± 23 3330 ± 49 NF161 10-5M 277 ± 28 3885 ± 33
NF161 10-6M 288 ± 28 3452 ± 74 NF161 10-6M 280 ± 22 3905 ± 55
NF177 10-4M 260 ± 21 3660 ± 84 NF177 10-4M 268 ± 17 3875 ± 42
NF177 10-5M 277 ± 15 3280 ± 94 NF177 10-5M 256 ± 22 4005 ± 35
NF177 10-6M 300 ± 24 3220 ± 77 NF177 10-6M 292 ± 16 4055 ± 44
1. Effects on PGE2 and PGI2 production by simultaneous treatment with IL-1α (10 ng/ml) and NF161 or NF177. Twenty hours later, PGE2 and the 
stable metabolite of prostacyclin, 6-keto-PGF1α, were measured in the sample prepared from the medium by EIA as described in the Materials and 
Methods section (n = 3).
2. Effects of NF161 and NF177 on PGE2 and PGI2 production by pre-induced COX-2. IL-1α (10 ng/ml) was added and incubated for 20 h. The cells 
were washed and NF161 or NF177 were added for a further 30 min. After incubation, PGE2 and 6-keto-PGF1α were measured in the sample 
prepared from the medium (n = 3)Page 9 of 11
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